Drugs / LYB005
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06904222 | Apr 2025 → Aug 2026 overdue | respiratory syncytial virus infectious disease | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06442241 | Jul 2024 → Dec 2025 overdue | respiratory syncytial virus infectious disease | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07208461 | Oct 2025 → Mar 2026 overdue | respiratory syncytial virus infectious disease | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYB005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06442241 ↗ |
| Modality | Vaccine | “RSV vaccine candidate LYB005” NCT06442241 ↗ |
| Route | Intramuscular | “as an intramuscular injection” NCT06442241 ↗ |